SBIR/STTR Research Award

Targeted drug delivery to tumor microenvironment

Award identifier 37addb519a31629644f05d772cceb444c4fd4f5f32c61e74ac7c91ce1360d1c0Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$224,833

Program and phase

SBIR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
SIBTECH, INC.
Proposal award date
2015-03-20
Contract end date
2016-04-19
UEI
MB7SNF2LNJC9
Solicitation number
PA14-071
Topic code
102

Research abstract

DESCRIPTION provided by applicant The goal of this project is to test the feasibility of targeted delivery of andquot re programmingandquot liposomal drugs to tumor associated macrophages TAMs TAMs are the major component of tumor microenvironment that generally supports tumor growth and interferes with anti tumor therapy These effects are significantly mediated by about of TAMs that are located in tumor perivascular areas and are the major source of pro tumorigenic and pro angiogenic mediators specifically implicated in promotion of tumor angiogenesis and metastatic dissemination There is evidence that various re programming cues can be used to reduce the pro tumorigenic potential of TAMs creating an opportunity for more efficient anti cancer therapy To target perivascular TAMs we selected liposomal formulations of a TLR ligand poly I C that we named Lip PIC The TLR activation stimulates re polarization in TAMs which appears to be relatively safe as it is being developed for various vaccination protocols and at the same time rather efficient in tumor growth inhibition at least in animal tumor models We reasoned that Lip PIC would extravasate through the leaky tumor vasculature to perivascular space the very area of the location of perivascular TAMs To further increase the probability of targeted drug delivery to TAMs we propose to test Lip PIC decorated with annexin V that targets tumor cells undergoing apoptosis Pro tumorigenic TAMs are the known andquot eatersandquot of tumor apoptotic cells presenting an opportunity to use tumor apoptotic cells as andquot Trojan Horseandquot to feed Lip PIC to TAMs Given the complexity of tumor microenvironment that is impossible to reconstruct in tissue culture we reasoned that only in vivo system would be adequate for the proposed proof of principle experiments Therefore we will test our approach in orthotopic T luc mouse breast tumor xenografts in immunocompetent Balb c mice Our Specific Aims are Specific Aim Evaluate the effects of delivery of liposomal poly I C formulation to perivascular TAMs in a breast cancer tumor model Specific Aim Establish if delivery of liposomal poly I C to TAMs could be enhanced by recruitment of apoptotic cells indoxorubicin treated breast cancer model Accomplishing these Specific Aims will provide a proof of principle for using liposomal formulations for delivery of re programming drugs to perivascular TAMs in vivo We envision that the eventual commercial product will be a proprietary optimized liposomal formulation for targeting perivascular TAMs in primary tumor as a part of combination anti cancer therapy PUBLIC HEALTH RELEVANCE The goal of this project is to test the feasibility of targeted delivery of andquot re programmingandquot liposomal drugs to specific cells in tumor microenvironment in order decrease their tumor supporting potential and increase their tumor fighting capabilities Two strategies will be tested one based on delivering liposomal drugs to the same andquot neighborhoodandquot where tumor supporting cells reside and the other based on targeting liposomal drugs to dying tumor cells that are expected to serve as andquot Trojan Horseandquot in feeding pro tumorigenic cells in tumor microenvironment

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

31 SBIR/STTR records share this UEI (1996–2018). Reported award amounts total $10,831,410. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Energy, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.